New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.» Read More
Close on the heels of announcing the hiring of a Chief Talent Officer, Pfizer this morning named a new head of Global Research and Development to replace John LaMattina who had earlier said he'd be leaving the drug company. It was on LaMattina's watch that Pfizer's next potential breakout blockbuster drug, torcetrapib for cholesterol, failed in a late-stage clinical trial.
The Dow is sitting at a new high and you could argue that the move in the pharmaceuticals sector today is largely market related with Dow components Merck, Pfizer and Johnson & Johnson all trading up. As I write this the biggest dollar gainer in the group is Eli Lilly. But the largest percentage gainer is Schering-Plough.
If the FDA approves this company's much-anticipated drug, the stock could pop.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Stocks ended Friday down slightly as dollar weakness sparked inflation concerns but losses were limited by solid U.S. consumer data. "Housing is slowing down but the U.S. consumer isn't," said Robert Froehlich of DWS Scudder. "The numbers today show that this dichotomy is in place and housing is in trouble but the consumers keep shopping."
U.S. regulators have not approved Novartis's Prexige painkiller, the Swiss drugmaker said on Thursday, in an expected move after Australia withdrew the drug due to concerns over liver side effects.
Merck said it halted a mid-stage trial of an investigational HIV vaccine because it proved ineffective at preventing and treating the disease.
The cancer drug Erbitux unexpectedly extended survival in a trial of patients with advanced lung cancer, sending shares of its maker, ImClone Systems, soaring as much as 24 percent.
Call it a stellar, mythic merger. This morning Isis Pharmaceuticals (named after the goddess in Egyptian mythology) and Alnylam Pharmaceuticals (named after the center star in Orion's belt) announced they're forming a joint venture called Regulus Therapeutics, LLC (named after the brightest star in the constellation Leo). I'm sensing a theme here.
Merck said Thursday the New Jersey Supreme Court has reversed a lower court ruling that had granted nationwide class-action status to insurers seeking reimbursement for past spending on Vioxx, the drugmaker's withdrawn arthritis treatment.
The gloves are off. Overnight, Pfizer came out with a new study on the world's top-selling drug, Lipitor, for cholesterol. The company says if you switch from its drug to generic Zocor you've got a 30% greater chance of dying from a heart attack, stroke or some other "major cardiovascular" event.
As I was gearing up to come back to work from my extended holiday weekend I searched some of my mainstay internet sources for information and tips yesterday including cafepharma.com. It's filled with pharmaceutical and biotech company message boards with postings mostly from sales reps complaining, providing job applicants with salary and benefits details, occasionally revealing the latest internal memo, and frankly, spreading rumors and gossip.
U.S. lawmakers returning from their summer break are expected to consider patent law changes that have pitted two of America's most invention-dependent industries against each other.
Stocks rallied after President Bush outlined his plan to help distressed homeowners, and Federal Reserve Chairman Ben Bernanke said the Fed will act as needed to address credit concerns.
Benefits of an experimental AIDS drug developed by Merck & Co appear to outweigh risks, according to U.S. Food and Drug Administration staff documents released Friday ahead of an advisory panel meeting.
Elan, Merck, Amazon, Qualcomm and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Schering-Plough and Merck Tuesday said U.S. regulators had accepted the marketing application for their experimental allergy drug, which combines two widely used existing treatments into a single tablet.
We've known that Merck has been testing its cervical cancer vaccine Gardasil on young men (16-23 years old). The company says major data on those clinical trials are expected next year and could help Merck win FDA approval of the shots for males as well as females. The first-of-its-kind product has already sparked a sociopolitical controversy with its recommended use for young women. Imagine the brouhaha if or when Merck starts selling it for young men.
British animal health authorities imposed restrictions around a second site amid fears that the outbreak of foot and mouth disease had spread from an initial control zone.
If things DO get worse out there, you're going to need a stock that is completely insensitive to the state of the economy. In the end, our narcissism could be what saves our portfolios.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
In very early trading MRK shares are rallying this morning on the wings of an upgrade at Cowen & Co. by analyst Steve Scala from Neutral to Outperform. He's been at a Neutral since a year and one month ago when the stock was sitting in the 30s. Today it's in the low 50s.